Integra LifeSciences financials
$16.64+2.27%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $418.8M | $391.9M | $434.9M | $402.1M | $415.6M | $382.7M | $442.6M | $380.8M | $418.2M | $368.9M | $397.0M | $382.4M |
| Gross profit | $219.7M | $217.0M | $220.9M | $207.0M | $209.3M | $194.4M | $249.1M | $200.2M | $225.9M | $206.8M | $226.5M | $218.3M |
| Gross margin | 52.5% | 55.4% | 50.8% | 51.5% | 50.4% | 50.8% | 56.3% | 52.6% | 54.0% | 56.1% | 57.0% | 57.1% |
| Operating income | $19.3M | $11.5M | $23.0M | $11.8M | -$512.7M | -$15.5M | $35.6M | -$8.2M | -$3.0M | $4.0M | $36.0M | $26.6M |
| Net income | $4.5M | -$4.6M | -$1.7M | -$5.4M | -$484.1M | -$25.3M | $19.4M | -$10.7M | -$12.4M | -$3.3M | $19.8M | $19.5M |
| Net margin | 1.1% | −1.2% | −0.4% | −1.3% | −116.5% | −6.6% | 4.4% | −2.8% | −3.0% | −0.9% | 5.0% | 5.1% |
| Diluted EPS | $0.06 | $-0.06 | $-0.02 | $-0.07 | $-6.31 | $-0.33 | $0.25 | $-0.14 | $-0.16 | $-0.04 | $0.25 | $0.24 |
| EBITDA | $57.4M | $49.9M | $61.5M | $50.3M | $36.4M | $21.7M | $73.2M | $27.8M | $33.7M | $34.5M | $36.0M | $57.2M |
| Operating cash flow | $22.8M | $9.8M | $11.8M | $40.9M | $8.9M | -$11.3M | $50.7M | $22.5M | $40.4M | $15.8M | $58.8M | $26.8M |
| Free cash flow | $10.5M | -$5.0M | -$5.4M | $25.8M | -$11.2M | -$40.2M | $21.1M | -$7.2M | $10.7M | $291.0K | $34.2M | $13.7M |
| Diluted shares | 78.2M | 77.0M | 76.8M | 76.8M | 76.7M | 76.5M | 76.4M | 76.4M | 77.4M | 77.7M | 78.1M | 79.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $214.4M | $236.8M | $235.0M | $232.2M | $217.9M | $239.1M |
| Short-term investments | $59.7M | $28.7M | $28.7M | $35.7M | $35.7M | $34.2M |
| Total debt | $1.87B | $1.87B | $1.86B | $1.83B | $1.84B | $1.84B |
| Total assets | $3.56B | $3.58B | $3.60B | $3.65B | $3.67B | $4.05B |
| Total liabilities | $2.52B | $2.54B | $2.56B | $2.61B | $2.63B | $2.53B |
| Shareholders' equity | $1.04B | $1.04B | $1.04B | $1.04B | $1.04B | $1.52B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology